http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
배중원(Joong-Won Bae),송재훈(Jae-Hoon Song),전향식(Hang-Sig Jeon),남기욱(Gi-Wook Nam),이한성(Han-Seong Lee) 한국항공우주연구원 2006 항공우주기술 Vol.5 No.2
위성항법시스템(GNSS)을 민간항공 분야에 활용하기 위해서는 국제민간항공기구가 정한 비행단계별 정확성(Accuracy), 무결성(integrity), 연속성(continuity), 가용성(availability) 요구조건을 만족시켜야 한다. 본 논문에서는 GBAS, GRAS 등 지상기반 위성항법보강시스템 개발에 활용될 수 있는 GNSS 원격 무결성 감시시스템을 제안하고 개발결과에 대해 기술 한다. GPS 수신기와 안테나로 구성된 위성신호 수신장치는 RS-232 to TCP/IP 프로토콜 변환장치를 통해 데이터 처리 및 분석을 수행하는 신호처리장치의 Host PC에 연결되도록 설계되었다. 이는 GPS 수신기의 설치 위치 제한을 극복하고 수신기와 안테나 간의 물리적 거리를 줄일 수 있어 CPS 수선 신호의 열화를 방지할 수 있는 방법이다. CPS 데이터를 수신하여 처리하는 신호처리장치는 실시간 운용 및 후처리 운용이 가능하며 GBAS CAT-I 급의 무결성 알고리즘과 차분보정 정보 생성을 지원하는 개발 환경을 제공한다. GNSS is a satellite-based radio navigation aid. For using it in civil air navigation area, any GNSS service should meet the requirements of accuracy, integrity, continuity and availability in each flight phase established by ICAO. In this study, a remote integrity monitoring system(RIM3) for GNSS are proposed and explained to utilize it in the design of GNSS augmentation system such as GBAS and GRAS. The RIM5 consists of signal-in-space receiving subsystem and signal processing subsystem Each as receiver is connected to Host PC by the serial to ethernet converting device which is able to convert serial port connection to LAN port connection in order to exchange information via the internet. We can overcome the siting limitation of as receiver and antenna, and reduce signal loses in the cable between as antenna and receiver. This system is providing the development environment for GBAS CAT-I system.
S-8 Comparison of tenofovir versus entecavir therapy in nucleos(t)ide-naive chronic hepatitis B
( Boram Min ),( Joong Gi Bae ),( Hyun Seong Lee ),( Young Min Shin ),( Kyung Hye Park ),( Byung Uk Lee ),( Jae Ho Park ),( Byung Gyu Kim ),( Seok Won Jung ),( In Du Jeong ),( Sung-jo Bang ),( Jung Woo 대한내과학회 2016 대한내과학회 추계학술대회 Vol.2016 No.1
Backgrounds:?Entecavir (ETV) and tenofovir (TDF) are nucleoside analogues with high potency for profound and durable viral suppression and genetic barriers against resistance; these drugs are recommended for the first-line treatment of chronic hepatitis B (CHB) in current guidelines. But rare data are available on the comparison of TDF and ETV therapy in CHB patients with baseline high viral load (HVL), defined as having hepatitis B virus (HBV) DNA >8 log10 copies/mL (7.3 log10 IU/mL).?Methods:?We performed a retrospective analysis of the efficacy of TDF therapy, as compared to that of ETV therapy, in patients with HVL. A matched study population was constructed to compare the antiviral efficacy of TDF therapy and ETV therapy by a propensity score analysis. The primary endpoint was a virological response (VR), defined as an HBV DNA level of <12 IU/mL.?Results:?Three hundreds two patients were selected after matching propensity score with 1:1 ratio. VR was observed in 66.2% (100/151) of patients in the TDF group and in 63.6% (96/151) of the patients in the ETV group. The VR rates were not different between the two groups (78.1 vs. 76.2% at month 12, and 99.0 vs. 95.8% at month 24; log rank p=0.432). During therapy, 74.8% of patients in the TDF group, and 70.2% of patients in the ETV group had partial VR, respectively (p=0.367). ALT normalization rates also did not differ between both the treatment groups (94.2% and 92.1% in the TDF and ETV therapy groups, respectively; p=0.476). During therapy, 13.7% (18 of 131) of patients in the TDF group, and 21.2% (28 of 132) of patients in the ETV group achieved HBeAg seroconversion, respectively (p=0.111). Nineteen patients experienced a virological breakthrough. Among them, twelve patient (7.9 %) was in the TDF group and 7 patients (4.6 %) were in the ETV group (p=0.236). Conclusions:?In patients with a baseline HBV DNA level >8 log10 copies/mL (7.3 log10 IU/mL), TDF therapy was as effective as ETV therapy, in maintaining the viral suppression.